UnitedHealth Group (UNH) Raised Guidance, Is The Stock Still Cheap?

UnitedHealth Group (UNH) is back in focus after reporting second quarter results that beat expectations on revenue and adjusted earnings, lifting full year profit guidance and sending the stock sharply higher.

See our latest analysis for UnitedHealth Group.

The latest jump in UnitedHealth Group’s share price comes on top of a 30.42% 90 day share price return and a 50.91% total shareholder return over the past year. This suggests momentum has rebuilt after the 2025 setback, and the recent earnings beat has reinforced that shift.

If UnitedHealth Group’s earnings driven move has you looking across healthcare, this could be a useful moment to scan companies applying AI to care delivery and operations through the 39 healthcare AI stocks

After a 52 week high and a guidance reset that caught the market’s attention, the real issue for UnitedHealth Group now is simple: does the current price still offer an appealing balance between upside potential and downside risk?

Most Popular Narrative: 7.2% Overvalued

UnitedHealth Group last closed at $423.38, compared with a fair value of $395.00 in the most followed narrative, which frames the recent move as pricing in more than the authors see in the fundamentals.

The market is currently valuing UnitedHealth through the narrow lens of a traditional insurer struggling with Medicare Advantage (MA) rate cuts and CMS regulatory headwinds for 2027. We believe this is a major diagnostic error.

Read the complete narrative.

Want to see what drives that $395 fair value for UnitedHealth Group? The narrative leans heavily on a reset margin profile and a rerating of its data and services engine. Curious which cash flow and profitability assumptions sit under that view, and how they contrast with today’s insurance heavy market pricing?

Result: Fair Value of $395.00 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, UnitedHealth Group’s story could change quickly if regulatory decisions are tougher than expected or if execution within Optum and core insurance operations slips.

Find out about the key risks to this UnitedHealth Group narrative.

Another View: UnitedHealth Group Through a P/E Lens

Where the most followed narrative pegs UnitedHealth Group as 7.2% overvalued at a $395 fair value, the preferred P/E checks tell a different story. At 31.9x, the stock trades above the US Healthcare industry at 25.5x, yet below peers at 38.9x and under a 40.6x fair ratio that the market could move toward over time. For investors, that mix of premium, discount and fair ratio raises a simple question: is this pricing a cushion or a warning?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If you feel that the UnitedHealth Group story is finely balanced between caution and optimism, this may be a good time to review the details and weigh both sides for yourself by reading the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond UnitedHealth Group?

If UnitedHealth Group has sharpened your focus, do not stop here, use the Simply Wall St screener to uncover fresh stock ideas built from the same systematic approach.

• Target resilient compounding potential by scanning companies in the 49 high quality undervalued stocks that combine quality fundamentals with prices that currently sit below their assessed worth.
• Prioritize staying power and financial strength by checking the solid balance sheet and fundamentals stocks screener (47 results) for businesses with balance sheets that may handle tougher periods more comfortably.
• Spot early opportunities before the crowd by reviewing the screener containing 20 high quality undiscovered gems and seeing which underfollowed stocks still line up with robust fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com